Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mochida Enters Generic Anticancer Drug Market with Hospira Products
October 1, 2012
- Osaka District Court Rules Against Takeda in Actos Patent Dispute with 8 Generic Drug Makers
October 1, 2012
- Novartis Obtains Approval for COPD Drug Seebri, Copromotion Planned with Eisai
October 1, 2012
- Daiichi Sankyo, AZ to Step Up Promotion for Nexium upon Lifting of Long-Term Prescription Ban
October 1, 2012
- Eisai Shifts Production Management Structure to Unit-Based Structure by Product Portfolio
October 1, 2012
- One-product, Two-brand Marketing Comes under Fire at CSIMC; Japanese Like Competition between Partners
October 1, 2012
- Nihon Chouzai Expects to Reach Agreement on Price Negotiations by End of September Despite Differences in Desired Prices
September 28, 2012
- Dilution-Free Formulation Approved for Zometa: Novartis
September 28, 2012
- GSK Ties Up with Tokyo University Venture for New Drug Candidate Exploration
September 28, 2012
- Eisai, Santen Conclude Option Agreement in Ophthalmologic Field
September 27, 2012
- Over 50,000 Patients Treated with Eli Lilly’s Forteo in 2 Years since Launch
September 27, 2012
- Kyowa Kirin Takes Full Control of South Korean Subsidiary
September 27, 2012
- GSK Files NDA for ICS/LABA Combination Drug for Asthma, COPD in Japan
September 27, 2012
- Santen to Establish New Sales and Marketing Subsidiary in China
September 27, 2012
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…